Phase II clinical trial - Appareil pulmonaire

NIVOTHYM (EORTC-1525)
Appareil pulmonaire
Ouvert depuis le: 09.19.2021
Site: Paris
Public cible
Adulte
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Description de l'essai

Immunotherapy is a cancer treatment that involves using laboratory-made antibodies from a single cell type of immune system. These antibodies can identify proteins on cancer cells or normal proteins that can stimulate the growth of cancer cells. Antibodies attach to these proteins and kill cancer cells, block their growth or prevent them from spreading. Nivolumab blocks a protein called PD-1. The PD-1 protein is found on the surface of T cells, a type of white blood cell that directly helps the body's immune system fight disease. This protein prevents the immune system from destroying cancer. Nivolumab reactivates the immune response against cancer.